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Abstract In the yeast, Saccharomyces cerevisiae, two ubiqui-
tin-like modi¢cations, Apg12 conjugation with Apg5 and Apg8
lipidation with phosphatidylethanolamine, are essential for au-
tophagy and the cytoplasm-to-vacuole transport of aminopepti-
dase I (Cvt pathway). As a unique E1-like enzyme, Apg7 acti-
vates two modi¢ers (Apg12 and Apg8) in an ATP-dependent
manner and, for this activity, the carboxyl terminal 40 amino
acids are essential. For a better understanding of the function of
the carboxyl terminus of Apg7, we performed a sequential dele-
tion of the region. A mutant expressing Apg7vC17 protein,
which lacks the carboxyl 17 amino acids of Apg7, showed de-
fects in both the Cvt pathway and autophagy. Apg8 lipidation is
inhibited in the mutant, while Apg12 conjugation occurs nor-
mally. A mutant expressing Apg7vC13 protein showed a defect
in the Cvt pathway, but not autophagy, suggesting that the
activity of Apg7 for Apg8 lipidation is more essential for the
Cvt pathway than for autophagy. Mutant Apg7vC17 protein is
still able to interact with Apg8, Apg12 and Apg3, and forms a
homodimer, indicating that the deletion of the carboxyl terminal
17 amino acids has little e¡ect on these interactions and Apg7
dimerization. These results suggest that the carboxyl terminal
17 amino acids of Apg7 play a speci¢c role in Apg8 lipidation
indispensable for the Cvt pathway and autophagy.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Autophagy is a bulk degradation of intracellular proteins
and organelles in the lytic organelles, lysosome and vacuole
[1^4]. During autophagy, a cup-shaped membrane sac sur-
rounds cytosolic proteins and organelles non-selectively to
form an autophagosome. The autophagosome ¢nally fuses
with the lysosome/vacuole, and the contents sequestered into
autophagosomes are degraded by lytic enzymes in the lyso-
some/vacuole. In the initial step of the formation of autopha-
gosomes, a sequential reaction of two ubiquitin-like modi¢ca-
tions, Apg12 conjugation and Apg8/Aut7 lipidation, is essen-
tial in yeast (Fig. 1A) [5^8]. Apg12 is conjugated to Apg5 by
Apg7/Cvt2/Gsa7, an E1-like enzyme, and Apg10, an E2-like
enzyme, respectively (Fig. 1A, Apg12 conjugation) [9^13]. The
Apg12^Apg5 conjugate is essential for the formation of an
autophagosomal precursor [14]. Thereafter, Apg8 is conju-
gated to phosphatidylethanolamine (PE) by Apg7 and Apg3/
Aut1, the same E1-like enzyme and a second E2-like enzyme,
respectively [7,13,15^18]. The Apg8 lipidation is indispensable
for the localization of Apg8 to preautophagosomes (Fig. 1A,
Apg8 lipidation) [19].
These modi¢cations are also essential for a unique trans-
port, the cytoplasm-to-vacuole (Cvt) pathway of aminopepti-
dase I (Ape1) and K-mannosidase in yeast, Saccharomyces
cerevisiae [20^23]. Ape1 is synthesized in the cytoplasm as a
precursor (proApe1), and forms a homo dodecamer (Fig. 1B)
[24]. ProApe1 is packaged into a double-membrane structure
called Cvt vesicles (Fig. 1B, Cvt pathway) [25,26]. Cvt vesicles
target the vacuole and fuse with it [25]. After the degradation
of the inner membrane of the Cvt body by Cvt17/Aut5 lipase
[27,28], proApe1 is ¢nally processed to mature Ape1 by vac-
uolar proteases. The deletion of each of these APG/CVT/AUT
genes results in a defect of the Cvt pathway and autophagy,
indicating that both pathways share the same molecular ma-
chinery to form both Cvt vesicles and autophagosomes [29].
However, there are di¡erences between the Cvt pathway and
autophagy. While the Cvt pathway is constitutive, autophagy
is inducible. The Cvt pathway shows high cargo speci¢city,
but autophagy is a bulk degradation of protein and organelle.
The Cvt vesicle is smaller than the autophagosome (Fig. 1B)
[25].
Apg7 is an E1-like enzyme essential for both Apg12 con-
jugation and Apg8 lipidation, interacting with its substrates,
Apg12 and Apg8 (Fig. 1A, Apg7) [9,11^13]. Furthermore, a
comprehensive analysis of yeast proteins and co-immunopre-
cipitation experiments revealed that Apg7 also interacts with
Apg3 [13,16,30^33]. Apg7 forms an homodimer in yeast and
mammals [13,33]. In yeast, S. cerevisiae, we have shown that
the deletion of the carboxyl terminal 40 amino acids out of
630 amino acids of Apg7 (the C40 region) results in pleiotro-
pic phenotypes including defects in Apg7 homodimerization,
Apg12 conjugation, Apg8 lipidation, and interactions of Apg7
with Apg12, Apg8, and Apg3, while the active-site cysteine
and ATP-binding domain within Apg7, which are essential
for the activity of E1-like enzyme, are still present [33]. We
are interested in the C40 region within Apg7, because there is
0014-5793 / 03 / $22.00 E 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(03)00899-8
*Corresponding author. Fax: (81)-3-5802 5889.
E-mail address: kominami@med.juntendo.ac.jp (E. Kominami).
Abbreviations: GAD, GAL4-activating domain; GBD, GAL4 DNA
binding domain; HA, hemagglutinin; HA-Apg12, HA epitope-tagged
Apg12; HA-Apg8, HA epitope-tagged Apg8; PAGE, polyacrylamide
gel electrophoresis; PE, phosphatidylethanolamine; PMSF, phenyl-
methylsulfonyl £uoride; SDS, sodium dodecyl sulfate
FEBS 27587 27-8-03
FEBS 27587 FEBS Letters 551 (2003) 71^77
no report about the signi¢cance of the carboxyl terminal re-
gion with regard to E1 and E1-like enzymes other than Apg7.
Considering these pleiotropic defects derived from the dele-
tion of the C40 region, it is possible that the region is impor-
tant for regulation of the two modi¢cations. Before this in-
vestigation, we hypothesized two possibilities with regard to
the function(s) of the C40 region. One possibility is that the
C40 region would contain multiple domains essential for each
of homodimerization, Apg12 conjugation and Apg8 lipida-
tion. The other possibility is that the whole of the region
would be essential for all the functions. If the former is cor-
rect, a sequential deletion of the carboxyl terminus of the C40
region will result in a single defect of homodimerization,
Apg12 conjugation or Apg8 lipidation. To test this hypothe-
sis, we performed a sequential deletion analysis of the carbox-
yl terminal region of Apg7 in detail. We found that the car-
boxyl terminal 17 amino acids (residues 614^630 out of 630
amino acids) of Apg7 play an indispensable role speci¢c for
Apg8 lipidation, but not Apg12 conjugation or homodimeri-
zation.
2. Materials and methods
2.1. Strains, media, materials, and molecular biological techniques
Molecular biological and biochemical techniques were performed as
described previously [34]. Escherichia coli strain DH5K cells, the host
for plasmids and protein expression, were grown in Luria broth me-
dium in the presence of antibiotics as required. Yeast strains used in
this study are listed in Table 1. To construct plasmids expressing the
mutant Apg7pvCx series (Fig. 2A), the polymerase chain reaction was
performed with high ¢delity.
2.2. Antibodies
Polyclonal antibody against yeast aminopeptidase I (anti-Ape1) was
kindly provided by Dr. Daniel Klionsky. Monoclonal mouse anti-myc
(9E10), monoclonal mouse anti-hemagglutinin (anti-HA) (F7), and
polyclonal rabbit anti-HA (Y-11) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.3. Other techniques
Chemical cross-linking for recognition of Apg7 homodimerization
and co-immunoprecipitation was performed as described by Komatsu
et al. [33]. Two-hybrid analysis was performed as described by James
et al. [35] and Komatsu et al. [33] using strain PJ69-4A.
3. Results
3.1. The carboxyl terminal 17 amino acids are essential for the
Cvt pathway and autophagy
To localize the minimal region within the carboxyl terminus
of Apg7 essential for the Cvt pathway and/or autophagy, we
constructed plasmids expressing mutant Apg7 proteins, which
lack the carboxyl terminal amino acids as indicated in Fig.
2A. Each of the mutant proteins Apg7vC5, Apg7vC9,
Apg7vC11, Apg7vC13, and Apg7vC17 was expressed under
the control of their own promoter on a centromere-type plas-
mid in the apg7v mutant, which lacks the APG7 gene on the
chromosome. We ¢rst investigated whether these mutant pro-
teins result in a defect in the Cvt pathway, i.e. processing of
Ape1 under nutrient-rich conditions. Ape1 is synthesized in
the cytosol as a precursor (proApe1) (Fig. 1B). Thereafter,
proApe1 is assembled into a large Cvt complex composed in
part of multiple proApe1-dodecamers in the cytosol that be-
comes enwrapped within a double-membrane Cvt vesicle (Fig.
1B, Cvt vesicles). Upon completion, the cytosolic Cvt vesicle
targets the vacuole. As a result, proApe1 is processed to ma-
ture Ape1 by vacuolar protease(s). Therefore, a defect in the
Cvt pathway can be recognized as little accumulation of ma-
ture Ape1 in the cells. Cell lysates of the apg7v mutants ex-
pressing a series of mutant Apg7vC proteins were prepared
and separated by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE). Mature Ape1 and proApe1
were recognized by immunoblot analysis using anti-Ape1 anti-
Fig. 1. Schematic representation of ubiquitin-like modi¢cations in
autophagy and the Cvt pathway. A: Sequential reactions of two
ubiquitin-like modi¢cations in the formation of the autophagosome.
Apg12 is activated by Apg7, an E1-like enzyme, transferred to
Apg10, the ¢rst E2-like enzyme, and ¢nally conjugated to Apg5.
The Apg12^Apg5 conjugate is localized to a autophagosomal pre-
cursor. Thereafter, Apg8 is activated by the same Apg7, transferred
to Apg3, a second E2-like enzyme, and ¢nally conjugated to PE.
Apg8p lipidation is thought to occur on the autophagosomal pre-
cursor for formation of a cup-shaped preautophagosome. The pre-
autophagosome ¢nally enwraps the cytosolic proteins and compart-
ments during autophagy. B: Ape1 processing via the Cvt pathway
and autophagy. Ape1 is synthesized in the cytosol as a precursor
(proApe1), and forms a dodecamer. Under nutrient-rich conditions,
proApe1 is enwrapped into Cvt vesicles. The Cvt vesicle fused with
lysosome. Thereafter, proApe1 is processed to mature Ape1 by vac-
uolar protease(s) in the vacuole. This Cvt pathway is constitutive.
Contrary to the Cvt pathway, autophagy is signi¢cantly induced
under conditions of starvation. During autophagy, proApe1 is en-
wrapped into the autophagosome together with cytosolic proteins
and compartments. After fusion of the autophagosome with the
vacuole, proApe1 is processed to mature Ape1 by vacuolar pro-
tease(s).
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body. In the apg7v mutant that lacks the APG7 gene, little
mature Ape1 was recognized by immunoblotting using anti-
Ape1 antibody, while proApe1 was recognized (Fig. 2B,
apg7v). In the wild type strain, both proApe1 and mature
Ape1 were recognized well (Fig. 2B, wild type). In the
apg7v mutants expressing each of the Apg7vC13 and
Apg7vC17 proteins, little mature Ape1 was recognized, indi-
cating that the Ape1 processing was signi¢cantly impaired, as
was the case for the apg7v mutant (Fig. 2B, Apg7vC13 and
Apg7vC17). In the other apg7v mutants expressing each of
the Apg7vC9 and Apg7vC11 proteins, mature Ape1 was rec-
ognized well, as was the case for the wild type (Fig. 2B,C).
These results indicate that the carboxyl terminal 13 amino
acids (residues 618^630 out of 630 amino acids) are essential
for the function of Apg7 for the Cvt pathway.
Under conditions of starvation, Ape1 is transported to the
vacuole via autophagy (Fig. 1B, Autophagy). If Apg7vC13
and Apg7vC17 proteins show a functional defect in autopha-
gy in addition to the Cvt pathway, proApe1 will not be pro-
cessed to mature Ape1 in the apg7v mutants expressing each
of the Apg7vC13 and Apg7vC17 proteins even under condi-
tions of starvation. To investigate this issue, Ape1 processing
was examined under conditions of starvation (Fig. 2C). In the
apg7v mutant expressing Apg7vC13 protein, proApe1 was
processed to mature Ape1 well under the conditions (Fig.
2C, Apg7vC13, Starvation +), indicating that Ape1 is trans-
ferred to the vacuole via autophagy. In the apg7v mutant
expressing Apg7vC17 protein, little proApe1 was processed
even under the starvation conditions, as was the case for the
apg7v mutant (Fig. 2C, Starvation +, Apg7vC17 vs. apg7v).
To con¢rm that the apg7v mutant expressing Apg7vC17
protein has a defect in autophagy, we next investigated the
accumulation of autophagic bodies under conditions of star-
vation. When wild type cells were incubated under nitrogen-
starved conditions in the presence of phenylmethylsulfonyl
£uoride (PMSF), autophagic bodies were signi¢cantly accu-
mulated in the vacuole as described previously (Fig. 2D, wild
type) [2]. In the apg7v cells, few autophagic bodies were ac-
cumulated in the vacuole (Fig. 2D, apg7v). When Apg17vC17
protein was expressed in the apg7v mutant cells, few autopha-
gic bodies were accumulated in the vacuole of the mutant
cells, as was the case for the apg7v cells (Fig. 2D, Apg7vC17).
However, in the apg7v mutant expressing Apg7vC13 protein,
autophagic bodies were accumulated in the vacuole, as was
the case for the wild type (Fig. 2D, Apg7vC13). These results
indicate that the minimal carboxyl terminal region essential
for both the Cvt pathway and autophagy is the domain con-
taining 614^630 out of 630 amino acids within Apg7. This
region was designated the C17 domain.
3.2. The C17 domain within Apg7 is essential for Apg8
lipidation, but not Apg12 conjugation
Apg7 is an E1-like enzyme essential for Apg12 conjugation
and Apg8 lipidation, and the sequential reaction of two mod-
i¢cations plays an indispensable role in the Cvt pathway and
autophagy (Fig. 1A). Which modi¢cation is impaired in the
apg7v mutant expressing Apg7vC17 protein, Apg8 lipidation
only, Apg12 conjugation only, or both? We then ¢rst inves-
tigated Apg8 lipidation, which is essential for the formation of
a cup-shaped preautophagosome. To recognize Apg8 in each
apg7v mutant, HA epitope-tagged Apg8 (HA-Apg8) was ex-
pressed under the control of its own promoter on a centro-
mere-type plasmid. Apg8 lipidation in the wild type strain was
recognized as a mobility shift of Apg8 on SDS^PAGE, as
described previously (Fig. 3A, upper panel, wild type, Apg8-
PE) [15,19]. Little Apg8-PE was recognized in the apg7v mu-
tant expressing Apg7vC17 protein together with HA-Apg8
(Fig. 3A, upper and lower panels, Apg7vC17), while Apg8-
PE in the apg7v mutant expressing each of the Apg7vC5,
Apg7vC9, and Apg7vC11 proteins together with HA-Apg8
was recognized like that in wild type (Fig. 3A, upper and
lower panels). A small amount of Apg8-PE was recognized
in the apg7v mutant expressing Apg7vC13 and HA-Apg8
(Fig. 3A, upper panel, Apg7vC13). We next investigated the
amount of Apg8-PE under the starvation conditions. Even
under the starvation conditions, little Apg8-PE was recog-
nized in the apg7v mutant expressing Apg7vC17 protein to-
gether with HA-Apg8, and a small amount of Apg8-PE was
Table 1
Yeast strains, plasmids, and primers used in this study
Yeast strains Reference
Name Genotypes
PJ69-4A MATK ura3 leu2 his3 trp1 gal4v gal80v LYS2: :GAL1-HIS3 GAL2-ADE2 [35]
YIT701 MATK leu2-3,112 trp1 ura3-52 apg7: :LEU2 [11]
TID702 MATK leu2-3,112 trp1 ura3-52 apg7: :URA3 This study
APG7WT TID702 [CEN6 TRP1 APG7] This study
APG7DC5 TID702 [CEN6 TRP1 APG7vC5] This study
APG7DC9 TID702 [CEN6 TRP1 APG7vC9] This study
APG7DC11 TID702 [CEN6 TRP1 APG7vC11] This study
APG7DC13 TID702 [CEN6 TRP1 apg7vC13] This study
APG7DC17 TID702 [CEN6 TRP1 apg7vC17] This study
APG7WT-2 TID702 [CEN6 TRP1 APG7] [CEN6 LEU2 HA: :APG8] This study
APG7DC5-2 TID702 [CEN6 TRP1 APG7vC5] [CEN6 LEU2 HA: :APG8] This study
APG7DC9-2 TID702 [CEN6 TRP1 APG7vC9] [CEN6 LEU2 HA: :APG8] This study
APG7DC11-2 TID702 [CEN6 TRP1 APG7vC11] [CEN6 LEU2 HA: :APG8] This study
APG7DC13-2 TID702 [CEN6 TRP1 apg7vC13] [CEN6 LEU2 HA: :APG8] This study
APG7DC17-2 TID702 [CEN6 TRP1 apg7vC17] [CEN6 LEU2 HA: :APG8] This study
APG7WT-3 YIT701 [CEN6 TRP1 APG7] [CEN6 URA3 HA: :APG12] This study
APG7DC5-3 YIT701 [CEN6 TRP1 APG7vC5] [CEN6 URA3 HA: :APG12] This study
APG7DC9-3 YIT701 [CEN6 TRP1 APG7vC9] [CEN6 URA3 HA: :APG12] This study
APG7DC11-3 YIT701 [CEN6 TRP1 APG7vC11] [CEN6 URA3 HA: :APG12] This study
APG7DC13-3 YIT701 [CEN6 TRP1 apg7vC13] [CEN6 URA3 HA: :APG12] This study
APG7DC17-3 YIT701 [CEN6 TRP1 apg7vC17] [CEN6 URA3 HA: :APG12] This study
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recognized in the apg7v mutant expressing Apg7vC13 and
HA-Apg8 (Fig. 3A, middle and lower panels). These results
indicate that the C17 domain of Apg7 (614^630 out of 630
amino acids) is essential for Apg8 lipidation. With regard to
mutant Apg7vC13 protein, it showed a defect in the Cvt path-
way, but not autophagy (Fig. 2B^D). Therefore, the residual
activity of Apg7 for Apg8 lipidation will be su⁄cient for au-
tophagy, while more activity is required for the Cvt pathway
than for autophagy.
We next investigated the formation of the Apg12^Apg5
conjugate in the apg7v mutants expressing Apg7vC17 and
HA epitope-tagged Apg12 (HA-Apg12) proteins. HA-Apg12
was expressed in the strain under the control of its own pro-
moter on a centromere-type plasmid. The HA-Apg12^Apg5
conjugate (V70 kDa) was recognized by immunoblot analysis
using mouse monoclonal anti-HA (F7) antibody in the wild
type, while little conjugate was recognized in the apg7v mu-
tant lacking the APG7 gene (Fig. 3B, Apg7-myc and apg7v).
In the apg7v mutant expressing Apg7vC17 protein, the HA-
Apg12^Apg5 conjugate was recognized well. Therefore, we
conclude that the C17 domain is essential for Apg8 lipidation,
but not Apg12 conjugation.
3.3. Mutant Apg7vC17 protein can interact with Apg8, while it
causes a defect of Apg8 lipidation
The deletion of the C17 domain results in a defect of Apg8
lipidation, while the active-site cysteine (Cys507) and ATP-
binding domain are still present within Apg7vC17 protein.
However, it is likely that the loss of interaction of mutant
Apg7vC17 protein with Apg8 would cause the defect in
Apg8 lipidation, because the interaction of E1-like enzyme
(Apg7) with a substrate (Apg8) is indispensable for a further
reaction. To investigate this possibility, we examined the in-
teraction of Apg7 with Apg8 by two-hybrid analysis [35].
GAL4 DNA binding domain (GBD)-Apg8 (bait) and mutant
GAL4-activating domain (GAD)-Apg7vC17 (prey) were ex-
pressed in a tester strain, PJ69-4A, and cell growth was exam-
ined as described by Komatsu et al. [33]. The strain expressing
GAD-Apg7vC17 and GBD-Apg8 grew on the selective me-
dium as well as did the strain expressing wild type GAD-Apg7
(Table 2, Apg7^Apg8 interaction), indicating that Apg7vC17
protein interacts with Apg8. We further investigated the in-
teractions of Apg7vC17 protein with Apg12 and Apg3 by
two-hybrid analysis. However, there is no di¡erence between
Fig. 2. The carboxyl terminal 17 amino acids (the C17 domain) are essential for both the Cvt pathway and autophagy. A: Schematic represen-
tation of the deleted region of mutant Apg7vC proteins lacking the carboxyl terminal region. Cys507 within yeast Apg7 is an authentic active-
site cysteine. ATP-binding domain and Cys507 within Apg7 are essential for the activity of E1-like enzyme. Apg7vC17 protein lacks the region
of 614^630 residues out of 630 amino acids of Apg7. B: Ape1 processing under nutrient-rich conditions. Each mutant protein (Apg7vC5,
Apg7vC9, Apg7vC11, Apg7vC13, and Apg7vC17) was expressed in the apg7v mutant lacking the APG7 gene. Cells growing at mid-log phase
in the nutrient-rich medium (1% yeast extract, 2% polypeptone, and 2% glucose) were harvested. Total cell lysate was prepared, proteins in the
lysate were separated by SDS^PAGE, and mature Ape1 (Ape1) and the precursor of Ape1 (proApe1) were recognized by immunoblot analysis
using anti-Ape1 antibody. The apg7v mutants expressing each of the Apg7vC13 and Apg7vC17 proteins showed a defect in the maturation of
Ape1, as was the case for the apg7v mutant. C: Ape1 processing under starvation conditions. Cells at mid-log phase in the nutrient-rich me-
dium (Starvation 3) were transferred to the nitrogen-starvation medium (0.17% yeast nitrogen base without amino acids and ammonium sul-
fate, 2% glucose), and incubated at 30‡C for 1 h. Cells were harvested, and Ape1 processing was analyzed as described in panel B (Starvation
+). The apg7v mutant expressing Apg7vC17 proteins showed a defect in the maturation of Ape1, as was the case for the apg7v mutant.
D: Accumulation of autophagic bodies. Cells at mid-log phase were transferred to the nitrogen-starvation medium in the presence of PMSF,
and incubated at 30‡C for 18 h. apg7v, the apg7v mutant lacking the APG7 gene; wild type, the apg7v mutant expressing myc-tagged wild
type Apg7 protein; Apg7vC13, the apg7v mutant expressing Apg7vC13 protein; Apg7vC17, the apg7v mutant expressing Apg7vC17 protein.
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wild type Apg7 and mutant Apg7vC17 (Table 2, Apg7^Apg12
and Apg7^Apg3 interactions).
Another possible defect is that homodimerization of Apg7
will be signi¢cantly impaired in the apg7v mutant expressing
Apg7vC17 protein. We then investigated the homodimeriza-
tion of mutant Apg7vC17 protein using a non-cleavable
cross-linking reagent as described previously [33]. Mutant
Apg7vC17 protein formed a homodimer as in the case of
wild type Apg7 protein (Table 2, homodimerization). There-
fore, we conclude that there is little defect in Apg7 homodi-
merization and the interactions of Apg7 with two substrates
(Apg8 and Apg12) and an E2-like enzyme.
4. Discussion
We showed that the C17 domain within Apg7 is essential
Fig. 2 (Continued).
Table 2
Summary of the deletion analyses of the carboxyl terminal region of Apg7
Phenotypes apg7v wild type vC9 vC11 vC13 vC17
Cvt pathwaya 3 + + + 3 3
Autophagic pathwaya 3 + + + + 3
Defects in modi¢cations and interactions
Apg8 lipidationb 3 + + + S 3
Apg12^Apg5 conjugationb 3 + + + + +
Apg7p homodimerizationc 3 + + + + +
Apg7^Apg12 interactiond 3 + + + + +
Apg7^Apg8 interactiond 3 + + + + +
Apg7^Apg3 interactiond;e 3 + + + + +
aThe data in Fig. 2 are summarized.
bThe data in Fig. 3 are summarized.
cHomodimerization of Apg7 in the mutants was investigated by a cross-linking experiment as described previously [33].
dThese interactions were investigated by two-hybrid analysis as described previously [33].
eThe interaction of Apg7 with Apg3 was con¢rmed by immunoprecipitation as described previously [33].
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for Apg8 lipidation, but not Apg12 conjugation, resulting in
defects of the Cvt pathway and autophagy. However, mutant
Apg7vC17 protein still contains an active-site cysteine and
ATP-binding domain that are indispensable for the activity
of the E1-like enzyme, and interacts with Apg8, Apg12, and
Apg3 (Fig. 3 and Table 2). Considering that the Apg12^Apg5
conjugate is present in the apg7v mutant expressing
Apg7vC17 protein, the activity of the E1-like enzyme will
remain in the mutant Apg7vC17 protein. One possibility is
that the C17 domain would a¡ect the interaction of Apg3
with its target, PE. Apg8 lipidation is a quite unique ubiqui-
tin-like modi¢cation; the target of Apg8 is not a protein, but
a phospholipid, PE. Therefore, the C17 domain would have a
speci¢c function for Apg3 to recognize PE or to localize to an
autophagosomal precursor. Another possibility is that the
C17 domain is essential for the recognition of a factor of
the preautophagosomal structure (PAS) [36], on which Apg8
is constitutively localized. A preliminary experiment on the
subcellular fractionation of Apg7 by di¡erential centrifugation
indicated that a small amount of Apg7 is fractionated in the
fraction pelletable at 10 000Ug, while most of the Apg7 is
fractionated in the soluble fraction at 90 000Ug in yeast
(I. Tanida, T. Ueno, and E. Kominami, unpublished results).
We are now investigating the subcellular distribution of
Apg7vC17 protein and the co-localization of Apg7 with
Apg8. The analysis will reveal the regulatory function of
Apg7 in the two cooperative modi¢cations during the Cvt
pathway and autophagy.
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